MX2022014649A - Coctel de peptidos. - Google Patents
Coctel de peptidos.Info
- Publication number
- MX2022014649A MX2022014649A MX2022014649A MX2022014649A MX2022014649A MX 2022014649 A MX2022014649 A MX 2022014649A MX 2022014649 A MX2022014649 A MX 2022014649A MX 2022014649 A MX2022014649 A MX 2022014649A MX 2022014649 A MX2022014649 A MX 2022014649A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- seq
- mutant protein
- amino acids
- consecutive amino
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000008300 Mutant Proteins Human genes 0.000 abstract 5
- 108010021466 Mutant Proteins Proteins 0.000 abstract 5
- 230000037433 frameshift Effects 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 102100037936 Basic helix-loop-helix domain-containing protein USF3 Human genes 0.000 abstract 1
- 101000805924 Homo sapiens Basic helix-loop-helix domain-containing protein USF3 Proteins 0.000 abstract 1
- 101000923332 Homo sapiens Protein asteroid homolog 1 Proteins 0.000 abstract 1
- 102100032661 Protein asteroid homolog 1 Human genes 0.000 abstract 1
- 108091006740 SLC22A9 Proteins 0.000 abstract 1
- 102100035246 Solute carrier family 22 member 9 Human genes 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Abstract
Se describe un péptido capaz de inducir una respuesta inmunitaria contra: una proteína mutante con cambio de marco -1a de ASTE1, en la que el péptido comprende al menos 10 aminoácidos consecutivos de la SEC ID NO: 26; una proteína mutante con cambio de marco -1a de ???1ß, en la que el péptido comprende al menos 10 aminoácidos consecutivos de la SEC ID NO: 27; una proteína mutante con cambio de marco -1a de KIAA2018, en la que el péptido comprende un fragmento inmunogénico de una de las SEC ID NO: 9-12, en la que el fragmento comprende al menos 8 aminoácidos consecutivos de una de las SEC ID NO: 9-12; o una proteína mutante con cambio de marco -1a de SLC22A9, en la que el péptido comprende al menos 8 aminoácidos consecutivos de una de las SEC ID NO: 14-18. También se describe una mezcla de péptidos que comprende un primer y un segundo péptidos, cada uno seleccionado independientemente de uno de los péptidos descritos anteriormente y un péptido capaz de inducir una respuesta inmunitaria contra una proteína mutante con cambio de marco -1a de ?T?ß?2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20177183 | 2020-05-28 | ||
| PCT/EP2021/064415 WO2021239980A2 (en) | 2020-05-28 | 2021-05-28 | A peptide cocktail |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014649A true MX2022014649A (es) | 2022-12-15 |
Family
ID=70921797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014649A MX2022014649A (es) | 2020-05-28 | 2021-05-28 | Coctel de peptidos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230203130A1 (es) |
| EP (1) | EP4157335A2 (es) |
| JP (1) | JP2023529322A (es) |
| KR (1) | KR20230019859A (es) |
| CN (1) | CN115916251A (es) |
| AU (1) | AU2021279327A1 (es) |
| BR (1) | BR112022024074A2 (es) |
| CA (1) | CA3179221A1 (es) |
| CO (1) | CO2022018888A2 (es) |
| IL (1) | IL298500A (es) |
| MX (1) | MX2022014649A (es) |
| WO (1) | WO2021239980A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4367260A1 (en) | 2021-07-09 | 2024-05-15 | Hubro Therapeutics AS | A primer |
| WO2024052542A2 (en) | 2022-09-09 | 2024-03-14 | Hubro Therapeutics As | A peptide cocktail |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866323A (en) | 1995-04-07 | 1999-02-02 | Case Western Reserve University | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors |
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| AU2003232485A1 (en) | 2002-04-18 | 2003-10-27 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
| DK2572725T3 (en) | 2011-09-21 | 2015-09-21 | Ruprecht Karls Universität Heidelberg | MSI-specific frameshift peptides (FSP) for the prevention and treatment of cancer |
| BR112015013737B1 (pt) | 2012-12-13 | 2021-07-27 | Ruprecht-Karls-Universitãt Heidelberg | Peptídeos com alteração do quadro de leitura msiespecífico (fsp) para a prevenção e tratamento do câncer |
| CN110996971A (zh) * | 2017-06-02 | 2020-04-10 | 亚利桑那州立大学董事会 | 创建个性化犬癌症疫苗的方法 |
| EP3630152A4 (en) | 2017-06-02 | 2021-07-28 | Arizona Board of Regents on behalf of Arizona State University | UNIVERSAL CANCER VACCINES AND METHODS FOR THEIR MANUFACTURE AND USE |
| JP2021508475A (ja) * | 2017-12-28 | 2021-03-11 | グリットストーン オンコロジー インコーポレイテッド | 共有抗原を標的とする抗原結合タンパク質 |
| WO2020097184A1 (en) * | 2018-11-06 | 2020-05-14 | Icahn School Of Medicine At Mount Sinai | Peptides, compositions and vaccines for treatment of microsatellite instability hypermutated tumors and methods of use thereof |
| FI3840767T3 (fi) | 2019-05-29 | 2024-01-31 | Hubro Therapeutics As | Peptidejä |
-
2021
- 2021-05-28 CA CA3179221A patent/CA3179221A1/en active Pending
- 2021-05-28 JP JP2022572641A patent/JP2023529322A/ja active Pending
- 2021-05-28 KR KR1020227044249A patent/KR20230019859A/ko unknown
- 2021-05-28 MX MX2022014649A patent/MX2022014649A/es unknown
- 2021-05-28 CN CN202180038321.9A patent/CN115916251A/zh active Pending
- 2021-05-28 EP EP21729314.1A patent/EP4157335A2/en active Pending
- 2021-05-28 AU AU2021279327A patent/AU2021279327A1/en active Pending
- 2021-05-28 WO PCT/EP2021/064415 patent/WO2021239980A2/en unknown
- 2021-05-28 IL IL298500A patent/IL298500A/en unknown
- 2021-05-28 US US17/927,544 patent/US20230203130A1/en active Pending
- 2021-05-28 BR BR112022024074A patent/BR112022024074A2/pt unknown
-
2022
- 2022-12-26 CO CONC2022/0018888A patent/CO2022018888A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021239980A3 (en) | 2022-02-24 |
| CA3179221A1 (en) | 2021-12-02 |
| IL298500A (en) | 2023-01-01 |
| JP2023529322A (ja) | 2023-07-10 |
| US20230203130A1 (en) | 2023-06-29 |
| CN115916251A (zh) | 2023-04-04 |
| KR20230019859A (ko) | 2023-02-09 |
| AU2021279327A1 (en) | 2022-12-22 |
| WO2021239980A9 (en) | 2022-05-27 |
| EP4157335A2 (en) | 2023-04-05 |
| WO2021239980A2 (en) | 2021-12-02 |
| BR112022024074A2 (pt) | 2022-12-20 |
| CO2022018888A2 (es) | 2022-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014649A (es) | Coctel de peptidos. | |
| EP1420821B8 (en) | Immunologically significant herpes simplex virus antigens and methods for using same | |
| EP2258383A3 (en) | Antigenic peptides derived from telomerase | |
| HUP9901186A2 (hu) | Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra | |
| WO2002032451A8 (en) | Vaccine composition comprising an antigen and a peptide having adjuvant properties | |
| IL152625A (en) | Synthetic but not amyloidogenic immunogenic peptides equivalent to amyloid b to elicit an immune response to amyloid b and amyloid deposits | |
| MX2021014497A (es) | Peptidos. | |
| NZ570553A (en) | Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines | |
| ATE338121T1 (de) | Von muc-1 abgeleitete peptide | |
| AR018603A1 (es) | Un peptido, util para el tratamiento y/o profilaxis de la enfermedad de alzheimer y el sindrome de down, las composiciones farmaceuticas y vacunas que locontienen, el uso de dicho peptido para la preparacion de las composiciones farmaceuticas, una secuencia de aislado de adn, un plasmido o vector vi | |
| EP0962531A3 (en) | Interferon-gamma production inducing isolated polypeptide fragment and an isolated DNA fragment encoding said polypeptide | |
| MX9503362A (es) | Nuevos anticuerpos br96 mutantes y equivalentes funcionales que reaccionan con carcinomas humanos. | |
| GB9606040D0 (en) | Active peptide | |
| DE69836744D1 (de) | Gruppe a streptokokken-impfstoff | |
| WO2004014937A3 (en) | Thrombin peptide derivatives | |
| DE69121423D1 (de) | Rekombinante vakzine gegen coccidiose | |
| NZ592340A (en) | A method for making a virus vaccine compising Replikin peptides | |
| GB0107319D0 (en) | Bacteriophage-mediated immunisation | |
| WO2003090667A3 (fr) | Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16 | |
| NZ508892A (en) | Nucleic acid encoding a vaccine-induced mutant major surface antigen of a hepatitis B viral strain | |
| AU5776799A (en) | Modified hcv peptide vaccines | |
| WO1996017059A3 (en) | Receptor for cell-binding domain of thrombospondins | |
| WO2024052542A3 (en) | A peptide cocktail | |
| DE3751398T2 (de) | Substrat-Peptide. | |
| Werner | Natural and synthetic peptides (other than neuropeptides) endowed with immunomodulating activities |